Last year, the healthcare system faced a surge of COVID, influenza, and RSV cases, filling hospitals with children in critical condition. Despite the introduction of a promising new RSV treatment, nirsevimab, its rollout was hampered by supply shortages and logistical challenges. Daniel Dodson, MD, MS, a pediatric infectious disease specialist, explained that the limited supply required careful allocation to high-risk infants, leading to difficult decisions and impassioned pleas from caregivers.
For more resources about respiratory syncytial viruses, immunization, vaccines, and infants, check out PPN Resource Central, an expertly curated database of thousands of resources related to giving care to children — every day and in crises.
Resources:
- Nirsevimab (Beyfortus) – FAQs for Healthcare Professionals – Pediatric Pandemic Network
- Nirsevimab Frequently Asked Questions – American Academy of Pediatrics
- Nirsevimab for Prevention of RSV in Healthy Late -Preterm and Term Infants – The New England Journal of Medicine
- Immunizations to Protect Infants – CDC